These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 27580700)

  • 1. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
    Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
    BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
    DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
    Issa MM; Runken MC; Grogg AL; Shah MB
    Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker monotherapy in routine clinical care.
    Bengtsen MB; Heide-Jørgensen U; Borre M; Nørgaard M
    Prostate; 2023 Jul; 83(10):980-989. PubMed ID: 37057816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.
    Cindolo L; Fanizza C; Romero M; Pirozzi L; Autorino R; Berardinelli F; Schips L
    World J Urol; 2013 Jun; 31(3):665-71. PubMed ID: 23239103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS.
    Cindolo L; Berardinelli F; Fanizza C; Romero M; Pirozzi L; Tamburro FR; Pellegrini F; Neri F; Pitrelli A; Schips L
    Arch Ital Urol Androl; 2013 Dec; 85(4):200-6. PubMed ID: 24399122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
    Fenter TC; Davis EA; Shah MB; Lin PJ
    Am J Manag Care; 2008 May; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
    Pirozzi L; Sountoulides P; Castellan P; Presicce F; Lombardo R; Romero M; De Nunzio C; Tubaro A; Schips L; Cindolo L
    Curr Drug Targets; 2015; 16(11):1165-71. PubMed ID: 25981606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
    Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J;
    J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride.
    Yoshida T; Kinoshita H; Yoshida K; Mishima T; Taniguchi H; Yanishi M; Komai Y; Yasuda K; Sugi M; Matsuda T
    Urology; 2016 May; 91():154-7. PubMed ID: 26826590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group.
    Roehrborn CG; Bruskewitz R; Nickel GC; Glickman S; Cox C; Anderson R; Kandzari S; Herlihy R; Kornitzer G; Brown BT; Holtgrewe HL; Taylor A; Wang D; Waldstreicher J
    Eur Urol; 2000 May; 37(5):528-36. PubMed ID: 10765090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
    Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
    Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group.
    Kaplan S; Garvin D; Gilhooly P; Koppel M; Labasky R; Milsten R; Reddy P; Rosenberg S; Sussman D; White C; Lee M; Pappas F; Waldstreicher J
    Urology; 2000 Oct; 56(4):610-6. PubMed ID: 11018616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transurethral Resection of Prostate and Bleeding: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial to See the Efficacy of Short-Term Use of Finasteride and Dutasteride on Operative Blood Loss and Prostatic Microvessel Density.
    Bansal A; Arora A
    J Endourol; 2017 Sep; 31(9):910-917. PubMed ID: 28650680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.